GSK plc (LON:GSK) Insider Jonathan Symonds Acquires 1,500 Shares

GSK plc (LON:GSK) insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction on Friday, December 20th. The shares were bought at an average cost of GBX 1,315 ($16.53) per share, with a total value of £19,725 ($24,792.61).

Jonathan Symonds also recently made the following trade(s):

• On Wednesday, October 30th, Jonathan Symonds bought 7,150 shares of GSK stock. The shares were bought at an average cost of GBX 1,394 ($17.52) per share, with a total value of £99,671 ($125,277.78).

GSK Price Performance

GSK stock traded up GBX 25.50 ($0.32) during midday trading on Monday, reaching GBX 1,334 ($16.77). The company had a trading volume of 3,698,402 shares, compared to its average volume of 9,962,725. The company has a market capitalization of £54.43 billion, a price-to-earnings ratio of 1,180.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. GSK plc has a 1-year low of GBX 1,282.50 ($16.12) and a 1-year high of GBX 1,823.50 ($22.92). The stock has a 50 day moving average price of GBX 1,387.25 and a 200-day moving average price of GBX 1,507.27.

GSK Dividend Announcement

The company also recently declared a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be given a dividend of GBX 15 ($0.19) per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a dividend yield of 1.03%. GSK’s dividend payout ratio is 5,309.73%.

Analyst Ratings Changes

GSK has been the subject of several research reports. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Wednesday, December 11th. Berenberg Bank reduced their price target on GSK from GBX 1,820 ($22.88) to GBX 1,600 ($20.11) and set a “buy” rating for the company in a research note on Friday, November 29th. Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, August 28th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,850 ($23.25) price target on shares of GSK in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($22.70).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.